Illumina welcomes Eli Lilly executive, shares react to Barclays target lift
25.06.2026 - 16:41:32 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 16:40.
Illumina Inc. (US4523271090) adds a prominent pharma scientist to its board and draws a fresh look from Barclays. The genomics stock trades on the NASDAQ, where governance changes and analyst signals are closely watched by healthcare investors. A recent market comment highlights the reaction in morning trade.
New board member from Eli Lilly
According to a market report, Illumina has appointed Daniel M. Skovronsky to its board of directors. Skovronsky is Chief Scientific and Product Officer at Eli Lilly, giving Illumina direct access to senior biopharma expertise for its strategic decisions. The report links his background to Illumina’s innovation agenda.
The same commentary notes that Illumina shares advanced about 6.6 percent in morning trading after the appointment was announced. The move underscores how board composition can matter for a company whose technologies sit at the center of precision medicine and large-scale genomic programs. Illumina has seen repeated swings above 5 percent over the past year.
Barclays adjusts its view on Illumina
Alongside the governance change, Barclays analyst Luke Sergott has raised his price target on Illumina from 122 to 145 US dollars. He keeps an Underweight rating, but points to a growing preference for life science tools and diagnostics in the broader healthcare sector. The analyst commentary frames expectations for upcoming quarters.
The article also recalls that Illumina’s stock has posted 30.8 percent gains since the start of the year, reaching a 52-week high around 175.70 US dollars. For retail investors, the combination of year-to-date performance, target changes and sector positioning helps gauge how cautious or constructive Wall Street remains on the shares. Volatility data underline that Illumina has recorded 14 moves above 5 percent over the past year.
All news and analysis on the Illumina shares
Further corporate updates, price data and consensus estimates on Illumina are available in the dedicated topic section and via the company’s investor relations page.
The product behind the stock
Illumina generates revenue primarily through its next-generation sequencing platforms and consumables, including systems such as NovaSeq paired with reagents for whole-genome, exome and oncology panels. These instruments and kits are used by research labs, hospitals and biopharma companies to decode DNA and profile disease-related variants. A business overview describes Illumina as a global leader in sequencing and array technologies.
Where the shares trade today
Illumina shares (US4523271090) trade on NASDAQ under the ticker ILMN. As of 2026-06-24, 16:00 New York time, recent data show a closing price around 175 US dollars, with intraday highs near 177.76 US dollars in the latest session.
Key data on the Illumina shares
- Company: Illumina Inc.
- ISIN: US4523271090
- WKN: 927157
- Ticker: ILMN
- Trading venue: NASDAQ
- Price (as of 2026-06-24, 16:00): 175.09 USD
- Market cap: 27.0 billion USD (as of 2026-06-24)
- Sector / industry: Health Care - Life Sciences Tools & Services
- Index membership: S&P 500
- Next earnings date: 2026-08-06
Disclaimer: This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. All data are based on sources believed to be reliable but may be subject to change. Retail investors should conduct their own research or consult a licensed advisor before making investment decisions.
